JP6949818B2 - 運動精子ドメイン含有タンパク質2及びがん - Google Patents

運動精子ドメイン含有タンパク質2及びがん Download PDF

Info

Publication number
JP6949818B2
JP6949818B2 JP2018504932A JP2018504932A JP6949818B2 JP 6949818 B2 JP6949818 B2 JP 6949818B2 JP 2018504932 A JP2018504932 A JP 2018504932A JP 2018504932 A JP2018504932 A JP 2018504932A JP 6949818 B2 JP6949818 B2 JP 6949818B2
Authority
JP
Japan
Prior art keywords
cancer
mospd2
antibody
pharmaceutical composition
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018504932A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527333A (ja
JP2018527333A5 (cg-RX-API-DMAC7.html
Inventor
イチャック メンデール
イチャック メンデール
オシュラト プロフェータ−メイラン
オシュラト プロフェータ−メイラン
ヤニブ サレム
ヤニブ サレム
アナット ショハム
アナット ショハム
ニバ ヤコブ
ニバ ヤコブ
エヤル ブレイトバート
エヤル ブレイトバート
Original Assignee
バスキュラー バイオジェニックス リミテッド
バスキュラー バイオジェニックス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バスキュラー バイオジェニックス リミテッド, バスキュラー バイオジェニックス リミテッド filed Critical バスキュラー バイオジェニックス リミテッド
Publication of JP2018527333A publication Critical patent/JP2018527333A/ja
Publication of JP2018527333A5 publication Critical patent/JP2018527333A5/ja
Application granted granted Critical
Publication of JP6949818B2 publication Critical patent/JP6949818B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
JP2018504932A 2015-07-31 2016-07-29 運動精子ドメイン含有タンパク質2及びがん Active JP6949818B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562199571P 2015-07-31 2015-07-31
US62/199,571 2015-07-31
PCT/IB2016/054584 WO2017021857A1 (en) 2015-07-31 2016-07-29 Motile sperm domain containing protein 2 and cancer

Publications (3)

Publication Number Publication Date
JP2018527333A JP2018527333A (ja) 2018-09-20
JP2018527333A5 JP2018527333A5 (cg-RX-API-DMAC7.html) 2020-04-23
JP6949818B2 true JP6949818B2 (ja) 2021-10-13

Family

ID=57942495

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018504932A Active JP6949818B2 (ja) 2015-07-31 2016-07-29 運動精子ドメイン含有タンパク質2及びがん

Country Status (10)

Country Link
US (2) US20190040150A1 (cg-RX-API-DMAC7.html)
EP (2) EP3735977A1 (cg-RX-API-DMAC7.html)
JP (1) JP6949818B2 (cg-RX-API-DMAC7.html)
CN (1) CN108135933B (cg-RX-API-DMAC7.html)
AU (1) AU2016303474B2 (cg-RX-API-DMAC7.html)
CA (1) CA2991868C (cg-RX-API-DMAC7.html)
ES (1) ES2839456T3 (cg-RX-API-DMAC7.html)
IL (1) IL257260B (cg-RX-API-DMAC7.html)
NZ (1) NZ738875A (cg-RX-API-DMAC7.html)
WO (1) WO2017021857A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3735977A1 (en) 2015-07-31 2020-11-11 Vascular Biogenics Ltd. Motile sperm domain containing protein 2 and cancer
ES2963268T3 (es) 2015-07-31 2024-03-26 Immunewalk Therapeutics Inc Proteína 2 que contiene el dominio de esperma móvil e inflamación
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN112041336A (zh) * 2018-03-13 2020-12-04 脉管生物生长有限公司 针对mospd2和t细胞或nk细胞特异性分子的双特异性抗体
EP3597193A1 (en) 2018-07-16 2020-01-22 Universitat Autònoma de Barcelona Therapeutic use of afatinib in cancer
CN116710130A (zh) * 2020-09-10 2023-09-05 脉管生物生长有限公司 含活动精子结构域的蛋白质2抗体及其使用方法
IL301202A (en) 2020-09-10 2023-05-01 Vascular Biogenics Ltd Antibodies against MOTILE SPERM DOMAIN CONTAINING PROTEIN 2 and methods of using them
US20250277052A1 (en) * 2021-03-29 2025-09-04 Immunewalk Therapeutics, Inc. Motile sperm domain containing protein 2, integrin beta2 and cd63
USD1105906S1 (en) * 2023-11-29 2025-12-16 Ufp Industries, Inc. Removable clip
USD1106811S1 (en) * 2023-11-29 2025-12-23 Ufp Industries, Inc. Removable clip

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途
JP2004537969A (ja) * 2000-12-08 2004-12-24 インサイト・ゲノミックス・インコーポレイテッド 脂質関連分子
WO2002063005A2 (en) * 2001-02-06 2002-08-15 Incyte Genomics, Inc. Lipid-associated molecules
AU2002309917A1 (en) * 2001-05-18 2002-12-03 Incyte Genomics, Inc. Lipid-associated molecules
US20040171009A1 (en) * 2001-05-18 2004-09-02 Tang Y. Tom Lipid-associated molecules
WO2003025150A2 (en) * 2001-09-21 2003-03-27 Incyte Genomics, Inc. Lipid-associated molecules
DK1463487T3 (da) * 2001-12-19 2010-08-23 Res Dev Foundation Liposomal afgivelse af vitamin-E baserede forbindelser
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
US20090137687A1 (en) * 2003-02-28 2009-05-28 Oxigene, Inc. Compositions and Methods With Enhanced Therapeutic Activity
JP4810642B2 (ja) * 2004-11-30 2011-11-09 秋田県 癌転移抑制用トリテルペン誘導体及び該トリテルペン誘導体を用いた癌転移抑制用組成物
US20070218116A1 (en) 2006-03-14 2007-09-20 Schwendener Reto A Compositions and methods for the treatment of tumors and tumor metastases
WO2010042228A2 (en) * 2008-10-10 2010-04-15 Cornell University Methods for predicting disease outcome in patients with colon cancer
KR20110095288A (ko) * 2008-11-06 2011-08-24 바스큘라 바이오제닉스 리미티드 산화된 지질 화합물 및 이의 용도
US20120020954A1 (en) 2009-03-30 2012-01-26 Anat Achiron Methods of predicting clinical course and treating multiple sclerosis
DK2443449T3 (en) 2009-06-15 2017-05-15 Cardiodx Inc DETERMINATION OF RISK OF CORONARY ARTERY DISEASE
WO2011159951A2 (en) 2010-06-17 2011-12-22 Sanford-Burnham Medical Research Institute Targeting tumor associated macrophages using bisphosphonate-loaded particles
EP2420228A1 (en) * 2010-08-05 2012-02-22 Alpinia Laudanum Institute Of Phytopharmaceutical Sciences AG Composition comprising retinol, a precursor or a reaction product of it and a plant extract from at least one chamomilla plant for the treatment of cancer
DE102011005235B4 (de) 2011-03-08 2017-05-24 Sirs-Lab Gmbh Verfahren zum Identifizieren einer Teilmenge von Polynucleotiden aus einer dem Humangenom entsprechenden Ausgangsmenge von Polynucleotiden zur in vitro Bestimmung eines Schweregrads der Wirtsantwort eines Patienten
WO2012121679A1 (en) * 2011-03-09 2012-09-13 Agency For Science, Technology And Research Method of modulating phenotype of a renal cell cancer-associated monocyte or macrophage
EP2791101B1 (en) * 2011-12-12 2019-09-18 Vascular Biogenics Ltd. Treatment of non-alcoholic steatohepatitis
CN103592432B (zh) * 2013-10-15 2015-06-03 重庆市公安局 一种免疫磁珠分离精子与上皮细胞混合斑中精子的方法
ES2963268T3 (es) 2015-07-31 2024-03-26 Immunewalk Therapeutics Inc Proteína 2 que contiene el dominio de esperma móvil e inflamación
EP3735977A1 (en) 2015-07-31 2020-11-11 Vascular Biogenics Ltd. Motile sperm domain containing protein 2 and cancer
IL301202A (en) 2020-09-10 2023-05-01 Vascular Biogenics Ltd Antibodies against MOTILE SPERM DOMAIN CONTAINING PROTEIN 2 and methods of using them
US20250277052A1 (en) 2021-03-29 2025-09-04 Immunewalk Therapeutics, Inc. Motile sperm domain containing protein 2, integrin beta2 and cd63

Also Published As

Publication number Publication date
ES2839456T3 (es) 2021-07-05
EP3328401A4 (en) 2019-03-20
EP3328401B1 (en) 2020-10-14
IL257260A (en) 2018-03-29
US20190040150A1 (en) 2019-02-07
AU2016303474A1 (en) 2018-02-01
CA2991868C (en) 2025-05-27
NZ738875A (en) 2023-06-30
CA2991868A1 (en) 2017-02-09
AU2016303474B2 (en) 2022-06-16
US20210095044A1 (en) 2021-04-01
CN108135933B (zh) 2022-04-29
HK1254515A1 (en) 2019-07-19
EP3735977A1 (en) 2020-11-11
JP2018527333A (ja) 2018-09-20
IL257260B (en) 2022-09-01
CN108135933A (zh) 2018-06-08
WO2017021857A1 (en) 2017-02-09
EP3328401A1 (en) 2018-06-06
US11945875B2 (en) 2024-04-02

Similar Documents

Publication Publication Date Title
US11945875B2 (en) Motile sperm domain containing protein 2 and cancer
US9073982B2 (en) Targets for regulation of angiogenesis
US7815906B2 (en) Compositions and methods for restoring sensitivity to treatment with HER2 antagonists
ES2717908T3 (es) Anticuerpos S100A4 y usos terapéuticos de los mismos
WO2014007438A1 (ko) 페리오스틴에 대한 압타머 및 이를 포함하는 항암제 조성물
US11136383B2 (en) Methods and compositions for modulaton of transforming growth factor beta-regulated functions
JP6949817B2 (ja) 運動精子ドメイン含有タンパク質2及び炎症
US10928397B2 (en) Methods involving MenaINV in screening for inhibitors of cancer invasion and metastasis
JP2021517153A (ja) Mospd2およびt細胞またはnk細胞特異的分子に対する二重特異性抗体 電子出願された配列表の参照
JP7025034B2 (ja) 膵臓炎、腎損傷および腎臓癌を治療および予防するための組成物および方法
JP2015520744A (ja) ヒトの肺疾患および胃腸管系疾患の新規ケモカインマーカーであるcxcl17の使用
HK40041339A (en) Motile sperm domain containing protein 2 and cancer
WO2011119524A1 (en) Novel targets for regulation of angiogenesis
JP2021508709A (ja) 疾患及び障害の治療及び予防のための抗レナラーゼ抗体
HK1254515B (en) Motile sperm domain containing protein 2 and cancer
AU2023324170A1 (en) Compositions and methods for treating diseases and conditions associated with activation of the nlrp3 inflammasome
WO2024036192A2 (en) Compositions and methods for assessing the severity of and treating covid-19

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190705

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201007

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210608

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210608

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210618

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210804

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210825

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210922

R150 Certificate of patent or registration of utility model

Ref document number: 6949818

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250